An Interview with Cognoa’s CEO Brent Vaughan In the US, one in five children are living with a diagnosable behavioral health disorder; however, only 21% of those children who are diagnosed receive needed treatment. Often, parents have to wait one to three years to receive a proper and accurate diagnosis, and an individualized treatment plan for their child. For the last 15 years, the average…
Halim Abbas, Ford Garberson, Stuart Liu-Mayo, Eric Glover & Dennis P. Wall Scientific Reports volume 10, Article number: 5014 (2020) Cite this article 2 Altmetric | Metricsdetails Abstract Autism has become a pressing healthcare challenge. The instruments used to aid diagnosis are time and labor expensive and require trained clinicians to administer, leading to long wait times for at-risk children. We present a multi-modular, machine learning-based assessment of autism comprising three complementary modules…
Ronit Molko, Ph.D., BCBA-D describes how AI will become the norm of autism services, as it has in other industries, including Cognoa’s digital therapeutics that create a more proactive role for parents and pediatricians in the diagnostic and treatment processes to accomplish early intervention. Read full article here.
AAP 2018 Past President Joins Cognoa to Improve the Standard of Care for Children with Autism Through Greater Pediatrician Adoption of Digital Prescription Apps (Palo Alto, Calif.– March 5, 2020) – Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced today that renowned pediatrician and 2018 Past President of the American Academy of Pediatrics (AAP), Dr. Colleen…
PALO ALTO, Calif. — February 26, 2020 — Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced today that CEO, Brent Vaughan, will participate in a digital therapeutics panel discussion at the Cowen and Company 40th Annual Healthcare Conference with executives from Akili Interactive Labs, Click Therapeutics and Pear Therapeutics. The panel will take place at 1:30…
Pediatric digital therapeutics developer Cognoa has teamed up with Autism Learning Partners, a specialized treatment provider, to put its autism screening app in the hands of parents to help track their children’s development. Read the full article here.
PASADENA and PALO ALTO, Calif. – February 11, 2020 – Autism Learning Partners (“ALP”), a national leader in the treatment of autism and other developmental disabilities, and Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced today a partnership designed to accelerate the diagnosis of autism to enable interventions earlier, when there is the greatest potential to…
PALO ALTO, Calif. — February 10, 2020 — Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced today that three company executives will be on stage at the third annual DTx West 2020, taking place in San Mateo, California, February 18 to 20. All events take place on the first day of the conference, Tuesday, February 18.…
International Health Technology Publication Annual List Recognizes Innovation and Leaders in Health Technology Palo Alto, Calif., and London – January 29, 2020 – Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, has been named to the 2020 Global Digital Health 100 list by The Journal of mHealth. Cognoa’s digital therapeutics will advance the standard of care by…
Cognoa CMO, Sharief Taraman, MD, DABPN, DABPM, FAAP, authored a MedCity News Influencer article about the potential of digital therapeutics and ai to empower pediatricians and make early intervention possible for more children. Our mental and behavioral health is largely determined by how the brain develops during the first few years of life when the brain is most actively developing.…
